ITPR1 and metabolic dysfunction-associated steatohepatitis: In this context, drugs inhibiting IP3R, like dmXeB, have a promising future because they could potentially prevent or treat fatty liver and NASH, in addition to liver fibrosis, by reducing HSC activation.